SCHEMBL6754390

SCHEMBL6754390

NC(=S)c1cccc(NC(=O)/C=C/c2ccccc2Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.67
RAB9A P51151 8/20 0.67
KMT2A Q03164 8/20 0.67
SMN1; SMN2 Q16637 6/20 0.67
MEN1 O00255 6/20 0.67
NPC1 O15118 5/20 0.67
MAOB P27338 2/20 0.67
PKM P14618 1/20 0.67
NFKB1 P19838 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
TP53 P04637 3/20 0.61
THRB P10828 1/20 0.59
MAOA P21397 1/20 0.57
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
KDM4E B2RXH2 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6754395 1.00 MAPT (0.67) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6754393 1.00 MAPT (0.67) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6756777 0.86 RAB9A (0.70) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL8059586 0.86 MAPT (0.74) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6756779 0.86 RAB9A (0.70) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6756780 0.86 RAB9A (0.70) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL8059583 0.86 MAPT (0.74) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6757911 0.82 MAPT (0.74) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6757908 0.82 MAPT (0.74) MAPTRAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6757909 0.82 MAPT (0.74) MAPTRAB9AKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 MAPT 3247/4885RAB9A 1818/4885KMT2A 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.